News of World Medicine

Genome editing is one of the ways to defeat cancer

Studies of tumor therapy using CRISPR-Cas9 in an animal model that mimicked the development of aggressive brain cancer, glioblastoma, and metastatic ovarian cancer have shown a sharp decrease in the reproduction of malignant cells in the body.

However, the scientists have faced one problem. The problem was a failure in the editing system deliver in CRISPR-Cas9 technology. The molecules were too large to be embedded in small structures. Scientists from Tel Aviv University, who conducted these studies, used to deliver CRISPR-Cas9 components as lipid-coated nanoparticles ranging in size from 71 to 80 nm to malignant cells. The injected intracerebral nanoparticles contain 2 types of RNA: messenger RNA (measures the genetic code of tumor cells) and transfer RNA (indicates the gene editing zone). This new approach did not reveal the side effects typical for chemotherapy, and the malignant cells destroyed by CRISPR-Cas9, so the tumors did not recur.